Search research articles
Contact Us
Filters
Showing results (521-530 of 563) with videos related to
Page
of 57
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Annals of Gastroenterology
|
March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
Hajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Alimentary Pharmacology & Therapeutics
|
June 20, 2022
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre
Susanna Meade, Kamal V Patel, Raphael P Luber, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Gut
|
September 3, 2020
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel
Richard Hansen, Susanna Meade, R Mark Beattie, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology
|
April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation
Nick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results
Gil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Inflammatory Bowel Diseases
|
November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
Adam S Faye, David T Rubin, Corey A Siegel, et al.
Page
of 57
Search research articles
Search
Showing results (521-530 of 563) with videos related to
Sort By:
Page
of 57
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Annals of Gastroenterology
|
March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
Hajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Alimentary Pharmacology & Therapeutics
|
June 20, 2022
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre
Susanna Meade, Kamal V Patel, Raphael P Luber, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Gut
|
September 3, 2020
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel
Richard Hansen, Susanna Meade, R Mark Beattie, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology
|
April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation
Nick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results
Gil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Inflammatory Bowel Diseases
|
November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
Adam S Faye, David T Rubin, Corey A Siegel, et al.
Page
of 57